Jaguar Health Files Definitive Proxy Statement

TL;DR

Jaguar Health filed its proxy statement for the annual meeting - vote your shares!

AI Summary

Jaguar Health, Inc. filed a definitive proxy statement (DEF 14A) on February 24, 2025, for its annual meeting of stockholders. The filing concerns the solicitation of proxies for the meeting, which will include the election of directors and other corporate matters. The company is headquartered at 200 Pine Street, Suite 400, San Francisco, CA.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including director elections and key company proposals, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing for a public company's annual meeting and does not contain new financial or operational risks.

Key Numbers

• 20250224 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
• 20250313 — Period of Report (The period for which the filing is made.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• 200 Pine Street, Suite 400, San Francisco, CA 94104 (address) — Company Business Address
• 0001193125-25-032742 (filing_id) — Accession Number

FAQ

From the Filing

0001193125-25-032742.txt : 20250224 0001193125-25-032742.hdr.sgml : 20250224 20250224070027 ACCESSION NUMBER: 0001193125-25-032742 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20250313 FILED AS OF DATE: 20250224 DATE AS OF CHANGE: 20250224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25654141 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 DEF 14A 1 d926095ddef14a.htm DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 JAGUAR HEALTH, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. 200 Pine Street, Suite 400, San Francisco, CA 94104 Tel: 415.371.8300 ● Fax: 415.371.8311 https://jaguar.health February 24, 2025 Dear Stockholder: You are cordially invited to attend a Special Meeting of Stockholders (the “Special Meeting”) of Jaguar Health, Inc. (the “Company”) to be held at 200 Pine Street, Suite 400, San Francisco, CA 94104, on Thursday, March 13, 2025, at 8:30 a.m., local time. At the Special Meeting you will be asked to: (i) approve the adoption of an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”) to effect, if approved and effected at all, a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share (the “Common Stock”) at a ratio not less than 1-for-15 and not greater than 1-for-40, the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before the one-year anniversary of the approval of this proposal, without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split”); and (ii) approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve proposal (i). It is important that your shares be represented and voted whether or not you plan to attend the Special Meeting in person. You may submit a proxy to have your shares voted on the Internet, by telephone or by completing and mailing a proxy card or voting instruction form. Submission of proxies over the Internet, by telephone or by mail will ensure your shares are represented at the Special Meeting. If you do attend the Special Meeting, you may, of course, withdraw your proxy should you wish to vote in person. Please read the enclosed information carefully be